Table 4: Selected Systemic Agents in Treatment of Diabetic Macular Edema.

Agent (# patients)Main OutcomesReference

Ruboxistaurin (686)Did not meet primary outcome measure at 30 months[102]
Fenofibrate (9795)Favorable outcomes versus placebo at average of 5 years[104]
Rosiglitazone (30)Some evidence of efficacy at 3 months, but also may worsen DME in some patients[107]